| NCT06106308 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-02-27 | 2027-01 | 2026-11 |
| NCT05593328 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | COMPLETED | PHASE2 | 2023-03-17 | 2024-12-09 | 2024-12-09 |
| NCT04752696 | Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma | COMPLETED | PHASE2 | 2021-06-07 | 2024-12-24 | 2024-12-24 |
| NCT03829410 | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | COMPLETED | PHASE1, PHASE2 | 2019-06-24 | 2024-01-29 | 2024-01-29 |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | COMPLETED | PHASE2 | 2018-08-14 | 2023-10-16 | 2023-10-16 |
| NCT03303339 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | COMPLETED | PHASE1, PHASE2 | 2017-11-17 | 2021-11-17 | 2021-11-17 |